UK MHRA Gets A Grip On Spiralling Clinical Trial Assessment Timelines
Executive Summary
The UK medicines regulator says the loss of experienced staff and the need to recruit and train new assessors resulted in temporary delays to clinical trial applications, but the crisis measures it put in place to address the situation mean it has now turned the corner.
You may also be interested in...
Singapore To Require GMP Evidence On Chemical Substance Drug Manufacturers
Singapore is taking steps to align good manufacturing practice requirements for chemical and biologic drug substance manufacturers and has rolled out a one-year transition plan for compliance.
EU Advances Plans For New Catalogs Of RWD Sources & Non-Interventional Studies
Users of the new catalogs will benefit from a modern technology with enhanced view, search, export and data submission functionalities, says the European Commission.
WHO Seeks Feedback On Gaps In Current QA & GMP Guidelines
The World Health Organization has shortlisted over 30 quality assurance and good manufacturing practice guidelines that are over seven years old or need a major review.